NeoGenomics, Inc. – NASDAQ:NEO

NeoGenomics stock price today

$6.19
-10.63
-63.22%
Financial Health
0
1
2
3
4
5
6
7
8
9

NeoGenomics stock price monthly change

+13.79%
month

NeoGenomics stock price quarterly change

+13.79%
quarter

NeoGenomics stock price yearly change

-17.90%
year

NeoGenomics key metrics

Market Cap
2.10B
Enterprise value
2.28B
P/E
-15.24
EV/Sales
4.48
EV/EBITDA
-24.61
Price/Sales
3.80
Price/Book
1.94
PEG ratio
N/A
EPS
-0.65
Revenue
610.66M
EBITDA
-8.54M
Income
-84.23M
Revenue Q/Q
13.86%
Revenue Y/Y
15.26%
Profit margin
-28.3%
Oper. margin
-30.04%
Gross margin
36.86%
EBIT margin
-30.04%
EBITDA margin
-1.4%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

NeoGenomics stock price history

NeoGenomics stock forecast

NeoGenomics financial statements

NeoGenomics, Inc. (NASDAQ:NEO): Profit margin
Jun 2023 146.91M -24.33M -16.56%
Sep 2023 151.95M -18.51M -12.19%
Dec 2023 155.55M -14.32M -9.21%
Mar 2024 156.24M -27.06M -17.32%
NeoGenomics, Inc. (NASDAQ:NEO): Analyst Estimates
Sep 2025 183.58M 4.91M 2.68%
Oct 2025 181.87M 5.60M 3.08%
Dec 2025 188.81M 9.53M 5.05%
Mar 2026 180.19M 3.22M 1.79%
  • Analysts Price target

  • Financials & Ratios estimates

NeoGenomics, Inc. (NASDAQ:NEO): Debt to assets
Jun 2023 1695108000 738.91M 43.59%
Sep 2023 1678241000 730.81M 43.55%
Dec 2023 1681229000 739.69M 44%
Mar 2024 1640339000 716.92M 43.71%
NeoGenomics, Inc. (NASDAQ:NEO): Cash Flow
Jun 2023 -1.54M 14.94M 64K
Sep 2023 -5.49M 20.82M 1.84M
Dec 2023 17.78M 17.19M 1.27M
Mar 2024 -25.91M 14.52M 816K

NeoGenomics alternative data

NeoGenomics, Inc. (NASDAQ:NEO): Employee count
Aug 2023 2,100
Sep 2023 2,100
Oct 2023 2,100
Nov 2023 2,100
Dec 2023 2,100
Jan 2024 2,100
Feb 2024 2,100
Apr 2024 2,100
May 2024 2,100
Jun 2024 2,100
Jul 2024 2,100

NeoGenomics other data

47.40% -43.07%
of NEO is owned by hedge funds
58.88M -53.69M
shares is hold by hedge funds

NeoGenomics, Inc. (NASDAQ:NEO): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 2587
Mar 2024 0 6112
May 2024 0 1049
Aug 2024 0 1040
Nov 2024 0 5175
Transaction Date Insider Security Shares Price per share Total value Source
Sale
OLIVO ALICIA C officer: General Counsel
Common Stock 5,175 $15.36 $79,478
Sale
OLIVO ALICIA C officer: General Counsel
Common Stock 1,040 $16.05 $16,695
Option
ZOOK ANTHONY P. director
Common Stock 11,336 N/A N/A
Option
ZOOK ANTHONY P. director
Restricted Stock Unit 11,336 N/A N/A
Option
TETRAULT LYNN A. director
Common Stock 11,336 N/A N/A
Option
TETRAULT LYNN A. director
Restricted Stock Unit 11,336 N/A N/A
Option
PEREZ DAVID BRIAN director
Common Stock 11,336 N/A N/A
Option
PEREZ DAVID BRIAN director
Restricted Stock Unit 11,336 N/A N/A
Option
KELLY MICHAEL AARON director
Common Stock 11,336 N/A N/A
Option
KELLY MICHAEL AARON director
Restricted Stock Unit 11,336 N/A N/A
Thursday, 19 December 2024
globenewswire.com
Wednesday, 11 December 2024
businesswire.com
Monday, 9 December 2024
businesswire.com
Thursday, 5 December 2024
businesswire.com
Tuesday, 3 December 2024
globenewswire.com
globenewswire.com
Thursday, 28 November 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Friday, 22 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Tuesday, 12 November 2024
reuters.com
Friday, 8 November 2024
businesswire.com
Thursday, 7 November 2024
globenewswire.com
Wednesday, 6 November 2024
zacks.com
Tuesday, 5 November 2024
seekingalpha.com
zacks.com
Monday, 4 November 2024
zacks.com
Tuesday, 29 October 2024
globenewswire.com
Monday, 28 October 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Tuesday, 15 October 2024
businesswire.com
Tuesday, 8 October 2024
zacks.com
Monday, 7 October 2024
globenewswire.com
Wednesday, 2 October 2024
gurufocus.com
prnewswire.com
Monday, 23 September 2024
businesswire.com
businesswire.com
Friday, 6 September 2024
globenewswire.com
Thursday, 29 August 2024
businesswire.com
Tuesday, 13 August 2024
globenewswire.com
  • What's the price of NeoGenomics stock today?

    One share of NeoGenomics stock can currently be purchased for approximately $6.19.

  • When is NeoGenomics's next earnings date?

    Unfortunately, NeoGenomics's (NEO) next earnings date is currently unknown.

  • Does NeoGenomics pay dividends?

    No, NeoGenomics does not pay dividends.

  • How much money does NeoGenomics make?

    NeoGenomics has a market capitalization of 2.10B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 16.07% to 591.64M US dollars.

  • What is NeoGenomics's stock symbol?

    NeoGenomics, Inc. is traded on the NASDAQ under the ticker symbol "NEO".

  • What is NeoGenomics's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of NeoGenomics?

    Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are NeoGenomics's key executives?

    NeoGenomics's management team includes the following people:

    • Mr. Douglas M. Brown Chief Strategy & Corporation Devel. Officer(age: 55, pay: $677,650)
  • How many employees does NeoGenomics have?

    As Jul 2024, NeoGenomics employs 2,100 workers.

  • When NeoGenomics went public?

    NeoGenomics, Inc. is publicly traded company for more then 21 years since IPO on 16 Mar 2004.

  • What is NeoGenomics's official website?

    The official website for NeoGenomics is neogenomics.com.

  • Where are NeoGenomics's headquarters?

    NeoGenomics is headquartered at 9490 NeoGenomics Way, Fort Myers, FL.

  • How can i contact NeoGenomics?

    NeoGenomics's mailing address is 9490 NeoGenomics Way, Fort Myers, FL and company can be reached via phone at +239 7680600.

NeoGenomics company profile:

NeoGenomics, Inc.

neogenomics.com
Exchange:

NASDAQ

Full time employees:

2,100

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

9490 NeoGenomics Way
Fort Myers, FL 33912

CIK: 0001077183
ISIN: US64049M2098
CUSIP: 64049M209